Is Symbicort a Rescue or Maintenance Inhaler?
Symbicort is a maintenance inhaler for long-term asthma and COPD control. It combines budesonide (a corticosteroid) and formoterol (a long-acting beta-agonist) to reduce inflammation and prevent symptoms. It's not approved as a rescue inhaler for sudden attacks.
How Does Symbicort's SMART Regimen Work?
In some cases, Symbicort uses the SMART (Single Maintenance and Reliever Therapy) approach, approved by the FDA for asthma in patients 12 and older. Patients take 1-2 puffs twice daily for maintenance, plus extra puffs as needed for symptoms (up to 12 total daily). This differs from traditional use, where a separate short-acting rescue inhaler like albuterol handles breakthroughs. SMART isn't for COPD and requires doctor guidance to avoid overuse.
What Happens If You Use Symbicort for Acute Attacks?
Symbicort isn't fast enough for immediate relief—formoterol takes 15 minutes to start working, versus albuterol's seconds. Guidelines from the Global Initiative for Asthma (GINA) recommend short-acting beta-agonists like albuterol or levalbuterol for rescue, not combination inhalers like Symbicort alone.
Symbicort vs. Common Rescue Inhalers
| Inhaler | Type | Key Ingredients | Onset Time | Primary Use |
|---------|------|-----------------|------------|-------------|
| Symbicort | Maintenance (SMART option for asthma) | Budesonide + formoterol | 15 minutes | Daily control, optional reliever |
| Albuterol (Ventolin, ProAir) | Rescue | Albuterol (short-acting beta-agonist) | 5-15 seconds | Acute symptoms |
| Levalbuterol (Xopenex) | Rescue | Levalbuterol | Seconds | Acute symptoms, fewer side effects |
Symbicort costs $300-400/month without insurance; generics launched in 2023 lower prices.
When Should You Pair Symbicort with a Rescue Inhaler?
Always have a rescue inhaler on hand, even on SMART. Use rescue if symptoms persist after Symbicort extra puffs or worsen rapidly. Over-reliance on any long-acting inhaler risks masking uncontrolled disease.
[1] FDA Symbicort Label
[2] GINA 2023 Asthma Guidelines
[3] DrugPatentWatch: Symbicort Patents